CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
London, United Kingdom and 26 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
London, United Kingdom and 66 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
London, Londonderry, United Kingdom and 73 other locations
This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...
Phase 2
London, United Kingdom and 37 other locations
in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...
Phase 1, Phase 2
London, United Kingdom and 25 other locations
study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non...
Phase 2
Sutton, United Kingdom and 16 other locations
targeting CD19 in pediatric patients with relapsed or refractory B cell acute lymphoblastic leukemia (B ALL) and relapsed or refractory B cell Non...
Phase 1
London, United Kingdom
additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...
Phase 1, Phase 2
London, United Kingdom and 19 other locations
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...
Phase 1
London, United Kingdom and 26 other locations
test the safety and efficacy of AUTO4 a CAR T cell treatment targeting TRBC1 in patients with relapsed or refractory TRBC1 positive selected T-Non...
Phase 1, Phase 2
London, United Kingdom and 4 other locations
Clinical trials
Research sites
Resources
Legal